Apollo Medical Holdings Inc. (NASDAQ:AMEH) Q3 2023 Earnings Call Transcript November 7, 2023 5:30 PM ET Company Participants Brandon Sim - Co-Chief Executive Officer Chan Basho - Chief Financial Officer Conference Call Participants Ryan Daniels - William Blair Brooks O'Neil - Lake Street Capital Markets Adam Ron - Bank of America David Larsen - BTIG Gary Taylor - TD Cowen Operator Good day, everyone, and welcome to today's Apollo Medical Holdings Third Quarter 2023 Earnings Call. [Operator Instructions]. To ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of Each Class Trading Symbol Name of Each Exchange on Which Registered Common Stock, $0.001 par value per share AMEH Nasdaq Capital Market FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___. Commission File ...

Apollo Medical Holdings Inc. (NASDAQ:AMEH) Q2 2023 Earnings Conference Call August 7, 2023 5:30 PM ET Company Participants Carolyne Sohn - Vice President of Investor Relations Brandon Sim - Co-Chief Executive Officer Chan Basho - Chief Financial Officer Conference Call Participants Jack Senft - William Blair Adam Ron - Bank of America Brooks O'Neil - Lake Street Capital Markets Operator Hello and welcome to the Apollo Medical Holdings' Second Quarter 2023 Financial Results Conference Call and Webcast. [Oper ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of Each Class Trading Symbol Name of Each Exchange on Which Registered Common Stock, $0.001 par value per share AMEH Nasdaq Capital Market FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___. Commission File ...

Financial Data and Key Metrics Changes - The company reported total revenue of $337.2 million for Q1 2023, a 28% increase from $263.3 million in the prior year quarter [20][24] - Adjusted EBITDA for the period was $29.8 million, with reported EBITDA of $24 million, up 1.2% from $23.7 million in the prior year [24] - Net income attributable to Apollo Med was $14.6 million, a 3% increase from $14.3 million in Q1 2022, with diluted earnings per share remaining flat at $0.31 [24] Business Segment Data and Key Metrics Changes - Care enablement segment revenue was $30.6 million, a 4% increase from $29.4 million in the prior year, but operating income decreased by 49.3% to $5.7 million due to investments in infrastructure and technology [21] - Care partners segment revenue increased by 30.4% to $314.7 million, with operating income rising 28.2% to $22.3 million, driven by organic membership growth and a favorable payer mix [22] - Care delivery segment revenue rose by 24.9% to $25.4 million, but the segment reported an operating loss of $1 million compared to an operating income of $1.1 million in the prior year due to expansion investments [23] Market Data and Key Metrics Changes - Membership under management in the care enablement segment was approximately 1.3 million, with about 650,000 members also in the care partners business [21] - The company has seen a 120% increase in unique members in newer markets like Nevada and Texas since acquiring Valley Oaks Medical Group [11] Company Strategy and Development Direction - The company is focused on growing membership in core and new geographies, moving members towards global risk contracts, and enabling providers to deliver excellent patient outcomes [10][12] - Recent acquisitions, including For Your Benefit, will allow the company to take on global risk for professional and institutional costs, enhancing its care coordination capabilities [12] - The company is also investing in the care delivery ecosystem through venture investments in innovative solutions for value-based care [14] Management's Comments on Operating Environment and Future Outlook - Management reiterated full-year 2023 guidance for both revenue and net income, emphasizing confidence in growth despite recent developments [18] - The company is streamlining operations and organizational structure to ensure profitability and margins remain on track [17] - Management expressed optimism about the long-term prospects of the business and operational strategy [26] Other Important Information - The company ended Q1 2023 with $274.6 million in cash and cash equivalents, down from $288 million at the end of 2022, while total stockholders' equity increased to $563.2 million [25] - The company repurchased $9.5 million worth of shares during the first quarter as part of a $50 million share repurchase authorization [25] Q&A Session Summary Question: Insights on G&A investments and care enablement - Management discussed investments in analytics and software engineering, which have contributed to increased G&A, and expect revenue to offset these costs in the near future [31][32] Question: Impact of Medicaid redetermination - Management indicated that the impact of Medicaid redetermination is included in guidance, with expectations to capture many members during the process [35] Question: LaSalle Medical Group contract termination - The termination was due to pricing terms not supporting long-term margins, which are typically in the 20% to 30% range [38] Question: Workforce trimming and Medicare pressures - Management confirmed a potential 5% workforce reduction to ensure robust margins in the care enablement business, with no significant pressure observed in the Medicare segment [42] Question: Opportunities with the Restricted Knox-Keene license - Management highlighted plans to operationalize the license across California, expecting initial breakeven results with long-term margin alignment [46][49] Question: ACO REACH program performance - Management noted that the ACO REACH program is currently breakeven, with ongoing evaluations to determine its long-term viability [56] Question: Timing for converting capitated lives under Knox-Keene - Management indicated that the conversion will be phased in over the next 18 to 24 months, with expectations for gradual revenue and EBITDA growth [59][61]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from ___ to ___ . Commission file number: 001-37392 Apollo Medical Holdings, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of i ...